## **Enantioselective Synthesis of Pachastrissamine (Jaspin B) Using Dirhodium(II)-Catalyzed C–H Amination and Asymmetric Dihydroxylation as Key Steps**

## Takayuki YAKURA,\* Seiichi SATO, and Yuya YOSHIMOTO

*Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama; Sugitani, Toyama 930–0194, Japan.* Received April 25, 2007; accepted June 1, 2007; published online June 1, 2007

**Enantioselective total synthesis of anhydrophytosphingosine pachastrissamine (jaspin B) was achieved using Sharpless asymmetric dihydroxylation and dirhodium(II)-catalyzed C–H amination as key steps.**

**Key words** pachastrissamine; total synthesis; C–H amination; jaspin B; dirhodium(II); asymmetric dihydroxylation

Pachastrissamine (jaspin B, **1**) was isolated from the Okinawan marine sponge *Pachastrissa* sp. by Higa and co-workers in 20021) and shortly after from a different sponge, *Jaspis* sp., by the Debitus group in  $2003<sup>2</sup>$  as a naturally occurring novel anhydrophytosphingosine derivative. It exhibited cytotoxic activities against several human carcinoma cell lines. Because of the impressive biological activity and its novel structural features, **1** has attracted much attention from synthetic chemists. Recently, several total syntheses of **1** from chiral compounds such as serine, phytosphingosine, and xylose have been reported.<sup>3-10)</sup> Dirhodium(II)-catalyzed C-H amination of carbamates to oxazolidinone derivatives has attracted much attention in recent synthetic organic chemistry as an important transformation<sup>11—18)</sup> because of the introduction of nitrogen to unactivated C–H bond. Recently we reported applications of dirhodium(II)-catalyzed C–H amination reaction to a synthesis of an immunomodulator  $(+)$  $conagemin<sup>19,20)</sup>$  and a facile preparation of optically active monoprotected 2-amino-2-methyl-1,3-propanediol.<sup>21)</sup> We report here the enantioselective total synthesis of **1** using Sharpless asymmetric dihydroxylation and dirhodium(II) catalyzed C–H amination as key steps.

We planned a simple and concise enantioselective synthesis of **1**. Our retrosynthetic analysis is depicted in Chart 1. Oxazolidinone (**2**) was selected as a temporary goal because this intermediate can be converted to pachastrissamine using alkali hydorolysis.4) The oxazolidinone ring of **2** should be constructed using dirhodium(II)-catalyzed C–H amination reaction of carbamate (**3**). In C–H amination reaction of **3**, it has four possible reactive C–H groups. The  $C_2$ –H is the most reactive among them because it is tertiary and  $\alpha$  to furan oxygen. However, as a result of the highly unfavorable ring strain associated with the *trans*-ring junction between the two



∗ To whom correspondence should be addressed. e-mail: yakura@pha.u-toyama.ac.jp © 2007 Pharmaceutical Society of Japan

five-membered rings formed by the reaction with  $C_2$ –H and also with C<sub>4</sub>–H<sub>B</sub>, selective reaction with C<sub>4</sub>–H<sub> $\alpha$ </sub> forming the *cis*-fused bicyclic system (**2**) is predicted. Although ketone formation by the reaction of rhodium nitrenoid with  $C_3$ –H is also possible, $12$ ) the large substituent at C-2 position might block its approach to the  $C_3$ –H. Compound (3) should be converted easily from alcohol (**4**). Compound (**4**) should be synthesized from diol (**5**) *via* iodination of primary alcohol and following tetrahydrofuran ring formation. The stereocenters of **5** should be constructed enantioselectively using Sharpless asymmetric dihydroxylation<sup>22)</sup> of the corresponding known  $(E)$ - $\alpha$ , $\beta$ -unsaturated ester (6).<sup>23,24)</sup>

Synthesis of the precursor of dirhodium-catalyzed C–H amination was started from known methyl (2*E*)-5-*p*methoxybenzyl(PMB)oxy-2-pentanoate (6),<sup>23,24)</sup> as illustrated in Chart 2. Asymmetric dihydroxylation of **6** was accomplished using AD-mix- $\alpha$  under usual conditions<sup>22)</sup> to give diol (**5**) in 89%. Optical purity of **5** was determined to be 98.1% ee by chiral HPLC analysis (hexane/*<sup>i</sup>* PrOH, 90/10, 0.5 ml/min, Chiralpak AD-H; Daicel Chemical Industries, Ltd.). Protection of diol with acetonide afforded **7**, which was reduced with diisobutylaluminum hydride (DIBAL-H) at -80 °C to provide aldehyde (**8**). Compound (**8**) was homologated by Wittig reaction to give (*Z*)-alkene (**9**) in 88% yield as a single stereoisomer. The (*Z*)-stereochemistry of **9** was determined by coupling constant  $(J=10.8 \text{ Hz})$  between vinyl protons in its <sup>1</sup>H-NMR spectrum. Both deprotection of PMB group and reduction of the C–C double bond of **9** proceeded simultaneously under hydrogenation conditions to produce alcohol (**10**) in 87% yield. Treatment of **10** with iodine and triphenylphosphine in the presence of imidazole yielded iodide (**11**) in quantative yield. Acid deprotection of **11** and following cyclization using potassium carbonate converted it into tetrahydrofuran (**4**) in 79% yield. According to the usual procedure,<sup>19—21)</sup> reaction of 4 with trichloroacetyl isocyanate in dichloromethane at room temperature gave the corresponding trichloroacetyl carbamate, which was treated with neutral alumina without purification to obtain the precursor (**3**) of C–H amination reaction in quantitative yield.

With the carbamate (**3**) in hand, we investigated C–H amination reaction of **3** (Table 1). Reaction of **3** with 10 mol% of dirhodium(II) tetraacetate, 4.2 equivalents of phenyliodine(III)





a) AD-mix- $\alpha$ , BuOH-H<sub>2</sub>O, 0 °C, overnight (89%); b) Me<sub>2</sub>C(OMe)<sub>2</sub>, CSA, rt, 12 h (quant); c) DIBAL-H,  $CH_2Cl_2$ , -80 °C, 1 h (97%); d)  $\overline{Ph}_3PCH_2C_{12}H_{25}Br$ , BuLi, THF, -20 °C, 1 h  $(88\%)$ ; e) H<sub>2</sub> (3 atm), Pd-C, EtOAc, rt, 3 h  $(87%)$ ; f)  $I_2$ ,  $Ph_3P$ , imidazole,  $CH_2Cl_2$ , rt, 1 h (quant); g) c-HCl, THF, rt, 2.5 h then  $K_2CO_3$ , MeOH, rt, 3 h (79%); h)  $CCl_3CON=C=0$ ,  $CH_2Cl_2$ , rt, 1 h then neutral  $Al_2O_3$  (quant).

Chart 2

Table 1. Rh(II)-Catalyzed C–H Amination of **3***<sup>a</sup>*)

Entry	Rh(II)	Solvent	Time (h)	Yield $(\% )$	
					13
	$Rh_2(OAc)_4$	CH <sub>2</sub> Cl <sub>2</sub>	13	No reaction	
2	$Rh_2(OAc)_4$	Benzene	13	$\Omega$	58
3	$Rh_2(OCOCPh_3)_4$	Benzene	13	19	40
4	$Rh(\exp)$ ,	Benzene	21	10	15

*a*) Reactions were carried out using 10 mol% of Rh(II) catalyst, 4.2 eq of PhI(OAc)<sub>2</sub>, and 6.9 eq of MgO under reflux.

diacetate, and 6.9 equivalents of magnesium oxide in dichloromethane under reflux,  $19-21$  however, gave no reaction with recovered starting **3** (Entry 1). A similar reaction in refluxing benzene for 13 h proceeded, unfortunately, to afford only undesired 2-tetradecatetrahydrofuran-3-one (**13**) in 58% yield with a complex mixture (Entry 2). The formation of **13** would be caused either by direct abstraction of  $C_3$ –H by rhodium nitrenoid intermediate (A) or through the generation of four-membered ring species  $(14)$  (Chart 3).<sup>12)</sup> This speculation spurred our use of a dirhodium(II) catalyst having bulkier ligands. When **3** was treated with dirhodium(II) tetra(triphenylacetate), 4.2 equivalents of phenyliodine(III) diacetate, and 6.9 equivalents of magnesium oxide in benzene under reflux for 13 h, the desired **2** was obtained in 19% yield (Entry 3).<sup>25)</sup> However, ketone (13) was still produced as a major product in 40% yield. Use of dirhodium dirhodium(II) bis( $\alpha, \alpha, \alpha', \alpha'$ -tetramethyl-1,3-benzenedipropanoate)  $[Rh_2(\exp)_2]^{26}$  gave low yields of both 2 and **13** with a complex mixture (Entry 4).

Finally, **2** was hydrolyzed using potassium hydroxide in ethanol under reflux for 3 h to afford  $(+)$ -pachastrissamine



a) aq. KOH, EtOH, reflux, 3 h; b)Ac<sub>2</sub>O, pyridine, rt, 12 h (85% in 2 steps)

Chart 4

(**1**), which was acetylated without purification to provide the *N*,*O*-diacetyl derivative (15), mp 108—111 °C,  $[\alpha]_D^{25} - 26.2^{\circ}$  $(c=0.30, \text{CHCl}_3)$  {lit.<sup>5)</sup> mp 95—98 °C,  $[\alpha]_D^{22}$  -22.6°  $(c=1.0,$ CDCl<sub>3</sub>), lit.<sup>7)</sup>  $[\alpha]_D$  -28.4° (c=1.0, CHCl<sub>3</sub>)}, in 85% yield from **2** (Chart 4). Spectroscopic data of **15**27) were identical to those of the reported sample.

In summary, we demonstrated a simple and concise enantioselective total synthesis of  $(+)$ -1 starting from  $\alpha$ , $\beta$ -unsaturated ester (**6**) using asymmetric dihydroxylation and C–H amination reaction as key steps. Further investigation for improvement of the C–H amination of **3** is now underway in our laboratory.

## **References and Notes**

- 1) Kuroda I., Musman M., Ohtani I. I., Ichiba T., Tanaka J., Gravalos D. G., Higa T., *J. Nat. Prod.*, **65**, 1505—1506 (2002).
- 2) Ledroit V., Debitus C., Lavaud C., Massiot G., *Tetrahedron Lett.*, **44**, 225—228 (2003).
- 3) Sudhakar N., Kumar A. R., Prabhakar A., Jagadeesh B., Rao B. V., *Tetrahedron Lett.*, **46**, 325—327 (2005).
- 4) Bhaket P., Morris K., Stauffer C. S., Datta A., *Org. Lett.*, **7**, 875—876 (2005).
- 5) van den Berg R. J. B. H. N., Boltje T. J., Verhagen C. P., Litjens R. E. J. N., van der Marel G. A., Overkleeft H. S., *J. Org. Chem.*, **71**, 836— 839 (2006).
- 6) Du Y., Liu J., Linhardt R. J., *J. Org. Chem.*, **71**, 1251—1253 (2006).
- 7) Ribes C., Falomir E., Carda M., Marco J. A., *Tetrahedron*, **62**, 5421— 5425 (2006).
- 8) Ramana C. V., Giri A. G., Suryawanshi S. B., Gonnade R. G., *Tetrahedron Lett.*, **48**, 265—268 (2007).
- 9) Lee T., Lee S., Kwak Y. S., Kim D., Kim S., *Org. Lett.*, **9**, 429—432 (2007).
- 10) Reddy L. V. R., Reddy P. V., Shaw A. K., *Tetrahedron: Asymmetry*, **18**, 542—546 (2007).
- 11) Espino C. G., Du Bois J., *Angew. Chem. Int. Ed.*, **40**, 598—600 (2001).
- 12) Espino C. G., Du Bois J., "Modern Rhodium-Catalyzed Organic Reactions," ed. by Evans P. A., Wiley-VCH, Weinheim, 2005, pp. 379— 416.
- 13) Davies H. M. L., Long M. S., *Angew. Chem. Int. Ed.*, **44**, 3518—3520 (2005).
- 14) Trost B. M., Gunzner J. L., Dirat O., Rhee Y. H., *J. Am. Chem*. Soc., **124**, 10396—10415 (2002).
- 15) Hinman A., Du Bois J., *J. Am. Chem. Soc.*, **125**, 11510—11511 (2003).
- 16) Huang H., Panek J. S., *Org. Lett.*, **5**, 1991—1993 (2003).
- 17) Parker K. A., Chang W., *Org. Lett.*, **5**, 3891—3893 (2003).
- 18) Parker K. A., Chang W., *Org. Lett.*, **7**, 1785—1788 (2005).
- 19) Yakura T., Yoshimoto Y., Ishida C., Mabuchi S., *Synlett*, **2006**, 930— 932 (2006).
- 20) Yakura T., Yoshimoto Y., Ishida C., Mabuchi S., *Tetrahedron*, **63**, 4429—4438 (2007).
- 21) Yakura T., Yoshimoto Y., Ishida C., *Chem. Pharm. Bull.*, **55**, in press (2007).
- 22) Sharpless K. B., Amberg W., Bennani Y. L., Crispino G. A., Hartung J., Jeong K.-S., Kwong H.-L., Morikawa K., Wang Z.-M., Xu D., Zhang X.-L., *J. Org. Chem.*, **57**, 2768—2771 (1992).
- 23) Oka T., Murai A., *Tetrahedron*, **54**, 1—20 (1998).
- 24) Cordero F. M., Gensini M., Goti A., Brandi A., *Org. Lett.*, **2**, 2475— 2477 (2000).
- 25) A suspension of **3** (38 mg, 0.116 mmol),  $PhI(OAc)_{2}$  (157 mg,

0.49 mmol), MgO (32 mg, 0.80 mmol), and  $Rh_2(OCOCPh_3)_4$  (16 mg, 0.012 mmol) in benzene (2.5 ml) was refluxed for 13 h. After the mixture was cooled to room temperature, it was passed through a short Celite pad and the filtrate was concentrated. The residue was chromatographed on silica gel (Et<sub>2</sub>O) to give  $2$  (7 mg, 19%) and **13** (13 mg, 40%). Spectroscopic data of **2** were identical to those of the reported sample. $4$ )

- 26) Espino C. G., Fiori K. W., Kim M., Du Bois J., *J. Am. Chem. Soc.*, **126**, 15378—15379 (2004).
- 27) Compound 15: mp 108—111 °C.  $[\alpha]_D^{25}$  -26.2° (*c*=0.30, CHCl<sub>3</sub>). IR (KBr) cm<sup>-1</sup>: 3215, 1740, 1647. <sup>1</sup>H-NMR (270 MHz, CDCl<sub>3</sub>)  $\delta$ : 0.88 (3H, t, J=6.6 Hz), 1.16-1.36 (24H, brm), 1.40-1.56 (2H, m), 1.97 (3H, s), 2.17 (3H, s), 3.60 (1H, t, *J*=8.1 Hz), 3.86—3.95 (1H, m), 4.08 (1H, t, J=8.5 Hz), 4.82 (1H, qd, J=8.1, 5.4 Hz), 5.38 (1H, dd, J=5.4, 3.5 Hz), 5.58 (1H, br d,  $J=7.8$  Hz). <sup>13</sup>C-NMR (67.5 MHz, CDCl<sub>3</sub>)  $\delta$ : 14.1, 20.7, 22.7, 23.2, 26.0, 29.29, 29.34, 29.46, 29.53, 29.57, 29.61, 29.64, 29.7, 31.9, 51.3, 70.0, 73.6, 81.2, 169.9 (2). HR-MS *m*/*z*: 383.30290 (Calcd for  $C_{22}H_{41}NO_4$  (M<sup>+</sup>): 383.30356).